OSMOTICA PHARM (OSMT)
(Delayed Data from NSDQ)
$3.98 USD
+0.05 (1.27%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.98 USD
+0.05 (1.27%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Osmotica Pharmaceuticals (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -66.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OSMOTICA PHARM (OSMT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSMOTICA PHARM (OSMT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 34.78% and -25.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OSMOTICA PHARM (OSMT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSMOTICA PHARM (OSMT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -2.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
OSMOTICA PHARM (OSMT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
OSMOTICA PHARM (OSMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Osmotica Pharmaceuticals (OSMT) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Osmotica Pharmaceuticals (OSMT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
OSMOTICA PHARM (OSMT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 58.33% and 11.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
OSMOTICA PHARM (OSMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
OSMOTICA PHARM (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSMOTICA PHARM (OSMT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 500.00% and 11.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
OSMT or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OSMT vs. ILMN: Which Stock Is the Better Value Option?
Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OSMT vs. QGEN: Which Stock Is the Better Value Option?
Moving Average Crossover Alert: Osmotica Pharmaceuticals
by Zacks Equity Research
Osmotica Pharmaceuticals is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Buy These 6 Best Value Stocks to Make the Most of P/B Ratio
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
Is OSMOTICA PHARM (OSMT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OSMT or QGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OSMT vs. QGEN: Which Stock Is the Better Value Option?